PARP inhibitors are being developed as therapeutic brokers for most cancers. Greater than six compounds have entered scientific trials. The vast majority of these compounds […]
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Impaired DNA harm response pathways might create vulnerabilities of most cancers cells that may be exploited therapeutically. One such selective vulnerability is the sensitivity of […]